Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 4;20(1):3.
doi: 10.1186/s12943-020-01291-6.

Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc

Affiliations
Review

Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc

Sarah K Madden et al. Mol Cancer. .

Abstract

c-Myc is a transcription factor that is constitutively and aberrantly expressed in over 70% of human cancers. Its direct inhibition has been shown to trigger rapid tumor regression in mice with only mild and fully reversible side effects, suggesting this to be a viable therapeutic strategy. Here we reassess the challenges of directly targeting c-Myc, evaluate lessons learned from current inhibitors, and explore how future strategies such as miniaturisation of Omomyc and targeting E-box binding could facilitate translation of c-Myc inhibitors into the clinic.

Keywords: Leucine zipper; Oncogene; Peptide; Protein-protein interaction; Transcription.

PubMed Disclaimer

Conflict of interest statement

JMM is an advisor to Sapience Therapeutics. The authors declare no other competing interests.

Figures

Fig. 1
Fig. 1
The structure and interaction partners of c-Myc. a Crystal structure of the c-Myc/Max dimer bound to E-box DNA (PDB ID 1NKP) [2]. b Scheme showing activating and repressing interaction partners, represented by double headed arrows, within the Myc/Max/Mxd network [3, 4]. c Different regions of c-Myc protein, including the MYC boxes (0, I, II, IIIa, IIIb, IV), Nuclear Localization Sequence (NLS) and bHLHZip domain along with the binding sites of its key interaction partners [–10]
Fig. 2
Fig. 2
Small molecule inhibitors of c-Myc. a IIA6B17 [73]. b 10058-F4 [76]. c Evolution of 10074-G5 [85]. d Evolution of Mycro1 and Mycro2 [88]. e MYCMI-6 [91]. f Evolution of MYCi [94]. g KJ-Pyr-9 [62]
Fig. 3
Fig. 3
Proposed mechanisms of Omomyc. Studies have suggested that: 1. Omomyc (Orange) homodimer blocks c-Myc/Max dimer from binding to E-box DNA (Red). 2. Omomyc binds to Max (Green), sequestering Max from c-Myc (Blue) and 3. In the presence of Omomyc, c-Myc levels are reduced due to proteasomal degradation, a process potentially tiggered by 2 [49, 105].
Fig. 4
Fig. 4
Overview of peptides and proteins that inhibit c-Myc, including E-box binding inhibitors (Omomyc, Max, ME47, Mxd and linked basic helices), inhibitors of c-Myc/Max binding (Omomyc, Max, Mxd, Monoclonal antibody, H1 peptide, a Max/aMip) and a c-Myc degradation promoter (Omomyc). Proteins marked with (*) are shown in their dimeric form [5, 99, 106, 107, 111, 112, 118, 120, 123]

Similar articles

  • Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy.
    Beaulieu ME, Jauset T, Massó-Vallés D, Martínez-Martín S, Rahl P, Maltais L, Zacarias-Fluck MF, Casacuberta-Serra S, Serrano Del Pozo E, Fiore C, Foradada L, Cano VC, Sánchez-Hervás M, Guenther M, Romero Sanz E, Oteo M, Tremblay C, Martín G, Letourneau D, Montagne M, Morcillo Alonso MÁ, Whitfield JR, Lavigne P, Soucek L. Beaulieu ME, et al. Sci Transl Med. 2019 Mar 20;11(484):eaar5012. doi: 10.1126/scitranslmed.aar5012. Sci Transl Med. 2019. PMID: 30894502 Free PMC article.
  • Targeting of the MYCN protein with small molecule c-MYC inhibitors.
    Müller I, Larsson K, Frenzel A, Oliynyk G, Zirath H, Prochownik EV, Westwood NJ, Henriksson MA. Müller I, et al. PLoS One. 2014 May 23;9(5):e97285. doi: 10.1371/journal.pone.0097285. eCollection 2014. PLoS One. 2014. PMID: 24859015 Free PMC article.
  • Omomyc Reveals New Mechanisms To Inhibit the MYC Oncogene.
    Demma MJ, Mapelli C, Sun A, Bodea S, Ruprecht B, Javaid S, Wiswell D, Muise E, Chen S, Zelina J, Orvieto F, Santoprete A, Altezza S, Tucci F, Escandon E, Hall B, Ray K, Walji A, O'Neil J. Demma MJ, et al. Mol Cell Biol. 2019 Oct 28;39(22):e00248-19. doi: 10.1128/MCB.00248-19. Print 2019 Nov 15. Mol Cell Biol. 2019. PMID: 31501275 Free PMC article.
  • MYC as a target for cancer treatment.
    Duffy MJ, O'Grady S, Tang M, Crown J. Duffy MJ, et al. Cancer Treat Rev. 2021 Mar;94:102154. doi: 10.1016/j.ctrv.2021.102154. Epub 2021 Jan 19. Cancer Treat Rev. 2021. PMID: 33524794 Review.
  • Targeting MYC with protein drugs.
    Shin JA. Shin JA. Prog Mol Biol Transl Sci. 2025;212:1-23. doi: 10.1016/bs.pmbts.2024.07.001. Epub 2024 Jul 19. Prog Mol Biol Transl Sci. 2025. PMID: 40122642 Review.

Cited by

References

    1. Nair SK, Burley SK. X-ray structures of Myc-Max and Mad-Max recognizing DNA: molecular bases of regulation by proto-oncogenictranscription factors. Cell. 2003;112:193–205. doi: 10.1016/S0092-8674(02)01284-9. - DOI - PubMed
    1. Diolaiti D, McFerrin L, Carroll PA, Eisenman RN. Functional interactions among members of the MAX and MLX transcriptional network during oncogenesis. Biochim Biophys Acta. 2015;1849:484–500. doi: 10.1016/j.bbagrm.2014.05.016. - DOI - PMC - PubMed
    1. Zhou Z-Q, Hurlin PJ. The interplay between Mad and Myc in proliferation and differentiation. Trends Cell Biol. 2001;11:S10–S14. doi: 10.1016/S0962-8924(01)02121-3. - DOI - PubMed
    1. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008;8:976–990. doi: 10.1038/nrc2231. - DOI - PubMed
    1. Montagne M, Beaudoin N, Fortin D, Lavoie CL, Klinck R, Lavigne P. The Max b-HLH-LZ can transduce into cells and inhibit c-Myc transcriptional activities. PLoS One. 2012;7:e32172. doi: 10.1371/journal.pone.0032172. - DOI - PMC - PubMed

Publication types

MeSH terms